Thyroid carcinoma.

Steven I Sherman; Peter Angelos; Douglas W Ball; Samuel W Beenken; David Byrd; Orlo H Clark; Gilbert H Daniels; Raza A Dilawari; Hormoz Ehya; William B Farrar; Robert F Gagel; Fouad Kandeel; Richard T Kloos; Peter Kopp; Dominick M Lamonica; Thom R Loree; William M Lydiatt; Judith McCaffrey; John A Olson; John A Ridge; Richard Robbins; Jatin P Shah; James C Sisson; Norman W Thompson; National Comprehensive Cancer Network

doi:10.6004/jnccn.2005.0021

Home/Archive/PubMed

PubMed · 16002006

Thyroid carcinoma.

View original source ↗Export metadata ↓

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

Biomarkers, Tumor Humans Multiple Endocrine Neoplasia Neoplasm Staging Thyroid Neoplasms Guideline Journal Article Practice Guideline

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Steven I Sherman, Peter Angelos, Douglas W Ball, Samuel W Beenken, David Byrd, Orlo H Clark, Gilbert H Daniels, Raza A Dilawari, Hormoz Ehya, William B Farrar, Robert F Gagel, Fouad Kandeel, Richard T Kloos, Peter Kopp, Dominick M Lamonica, Thom R Loree, William M Lydiatt, Judith McCaffrey, John A Olson, John A Ridge, Richard Robbins, Jatin P Shah, James C Sisson, Norman W Thompson, National Comprehensive Cancer Network. 2005. Thyroid carcinoma.. https://doi.org/10.6004/jnccn.2005.0021

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2022

High tumor amplification burden is associated with TP53 mutations in the pan-cancer setting.

Next-generation sequencing data is fundamentally changing the clinical management of patients with cancer. The most frequent genomic alterations in malignancy are mutations and amplifications, with a subset of tumors having multiple amplifications - "amplificators". We sought to understand the molecular correlates of high tumor amplification burden in a pan-cancer context. Using both national registries and a single-institution dataset, our results demonstrate that cancers with TP53 mutations (as compared to those with wild-type TP53) exhibited significantly higher tumor amplification burden across all datasets. Amplifications, generally associated with overexpression, may be potentially actionable secondary consequences of TP53 mutations.

Biomarkers, Tumor↗

PubMed2021

Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers.

BACKGROUND: While 2-4% of lung cancers possess alterations in BRAF, little is known about the immune responsiveness of these tumours. METHODS: Clinical and genomic data were collected from 5945 patients with lung cancers whose tumours underwent next-generation sequencing between 2015 and 2018. Patients were followed through 2020. RESULTS: In total, 127 patients with metastatic BRAF-altered lung cancers were identified: 29 tumours had Class I mutations, 59 had Class II/III alterations, and 39 had variants of unknown significance (VUS). Tumour mutation burden was higher in Class II/III than Class I-altered tumours (8.8 mutations/Mb versus 4.9, P < 0.001), but this difference was diminished when stratified by smoking status. The overall response rate to immune checkpoint inhibitors (ICI) was 9% in Class I-altered tumours and 26% in Class II/III (P = 0.25), with median time on treatment of 1.9 months in both groups. Among patients with Class I-III-altered tumours, 36-month HR for death in those who ever versus never received ICI was 1.82 (1.17-6.11). Nine patients were on ICI for >2 years (two with Class I mutations, two with Class II/III alterations, and five with VUS). CONCLUSIONS: A subset of patients with BRAF-altered lung cancers achieved durable disease control on ICI. However, collectively no significant clinical benefit was seen.

Biomarkers, Tumor↗

PubMed2007

Hepatoblastoma in a child with neurofibromatosis type I.

A major hallmark of NF1 is the development of benign tumors, including peripheral neurofibromas, plexiform neurofibromas, gliomas of the optic tract, other low grade gliomas, and pheochromocytomas. Hepatoblastoma have not been previously reported in patients with neurofibromatosis type 1. We present a case of a 9-month-old boy diagnosed with both hepatoblastoma and neurofibromatosis type 1. Hepatoblastoma occurs in association with several well-described cancer predisposition syndromes, including familial adenomatous polyposis, Beckwith-Wiedemann syndrome, Li-Fraumeni syndrome, trisomy 18, and glycogen storage disease type I. This paper describes a case of hepatoblastoma diagnosed in association with neurofibromatosis type 1.

Biomarkers, Tumor↗